Citations (66)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Jingbo Hu, Chunlin Yang, Hongbo Wang, Jing Li, Xueying Tan, Jinhui Wang, Bin Zhang & Yufen Zhao. (2019) An up-to-date evaluation of alogliptin benzoate for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 20:14, pages 1679-1687.
Read now
Read now
Dieter Ayers, Steve Kanters, Rachel Goldgrub, Monica Hughes, Ryo Kato & Nana Kragh. (2017) Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients. Current Medical Research and Opinion 33:9, pages 1653-1661.
Read now
Read now
Shishi Xu, Xinyue Zhang, Lizhi Tang, Fang Zhang & Nanwei Tong. (2017) Cardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review. Postgraduate Medicine 129:2, pages 205-215.
Read now
Read now
Daisuke Yabe & Yutaka Seino. (2016) Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation. Expert Opinion on Drug Safety 15:2, pages 249-264.
Read now
Read now
Joshua J Neumiller & Daniel Q Holland. (2016) Alogliptin + metformin combination for the treatment of type 2 diabetes mellitus. Expert Review of Endocrinology & Metabolism 11:1, pages 21-31.
Read now
Read now
Yoshifumi Saisho. (2015) Alogliptin benzoate for management of type 2 diabetes. Vascular Health and Risk Management 11, pages 229-243.
Read now
Read now
Hongyu Wang, Jinbo Liu & Hongwei Zhao. (2015) Emerging options for the treatment of type 2 diabetes in Chinese patients: focus on arterial function and alogliptin. Drug Design, Development and Therapy 9, pages 683-686.
Read now
Read now
Yutaka Seino & Daisuke Yabe. (2014) Alogliptin for the treatment of Type 2 diabetes. Expert Review of Endocrinology & Metabolism 9:6, pages 547-559.
Read now
Read now
Kohei Kaku, Mikiko Mori, Tatsuhiro Kanoo, Masafumi Katou & Yutaka Seino. (2014) Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase. Expert Opinion on Pharmacotherapy 15:15, pages 2121-2130.
Read now
Read now
Kohei Kaku. (2014) Efficacy of voglibose in type 2 diabetes. Expert Opinion on Pharmacotherapy 15:8, pages 1181-1190.
Read now
Read now
Yutaka Seino & Daisuke Yabe. (2014)
Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 15:6, pages 851-863.
Read now
Read now
John Gerich. (2013) Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. International Journal of General Medicine 6, pages 877-895.
Read now
Read now
Annalisa Capuano, Liberata Sportiello, Maria Ida Maiorino, Francesco Rossi, Dario Giugliano & Katherine Esposito. (2013) Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin. Drug Design, Development and Therapy 7, pages 989-1001.
Read now
Read now
Masanobu Aramaki. (2013) Alogliptin, but not voglibose, ameliorates dyslipidemia and LDL particle size in patients with impaired glucose tolerance or Type 2 diabetes. Clinical Lipidology 8:5, pages 533-540.
Read now
Read now
Kiyomi Masuda, Kazutaka Aoki, Kazunari Kamiko, Masahiro Takihata, Yuzuru Ito, Mieko Nagakura, Satsuki Kawasaki, Noriko Akema, Maki Hasegawa, Shigeru Nakajima, Kazuaki Shinoda, Shyoken Toumura, Seishi Tsunoda, Hitoshi Enomoto, Hidefumi Shimotomai & Yasuo Terauchi. (2013) Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a-day treatment with α-glucosidase inhibitors. Expert Opinion on Pharmacotherapy 14:9, pages 1111-1118.
Read now
Read now
Articles from other publishers (51)
Shuyan Gu, Xiaoqian Hu, Lizheng Shi, Xuemei Zhen, Xueshan Sun, Minzhuo Huang, Yuxuan Gu & Hengjin Dong. (2022) Choice of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine 11:23, pages 7094.
Crossref
Crossref
Shangyu Chai, Ruya Zhang, Ye Zhang, Richard David Carr, Yiman Zheng, Swapnil Rajpathak & Linong Ji. (2022) Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis. Frontiers in Endocrinology 13.
Crossref
Crossref
Ruili Yin, Yongsong Xu, Xin Wang, Longyan Yang & Dong Zhao. (2022) Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment. Molecules 27:10, pages 3055.
Crossref
Crossref
Rimei Nishimura, Mayumi Taniguchi, Tomomi Takeshima & Kosuke Iwasaki. (2021) Efficacy and Safety of Metformin Versus the Other Oral Antidiabetic Drugs in Japanese Type 2 Diabetes Patients: A Network Meta-analysis. Advances in Therapy 39:1, pages 632-654.
Crossref
Crossref
Guang Wang, Bing Wu, Lening Zhang, Xuefei Jin, Kun Wang, Wenzhou Xu, Bo Zhang & Heyuan Wang. (2021) The protective effects of trelagliptin on high‐fat diet‐induced nonalcoholic fatty liver disease in mice. Journal of Biochemical and Molecular Toxicology 35:4.
Crossref
Crossref
Chu Lin, Xiaoling Cai, Wenjia Yang, Fang Lv, Lin Nie & Linong Ji. (2020) Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus. BMC Medicine 18:1.
Crossref
Crossref
Peyman Nowrouzi-Sohrabi, Reza Tabrizi, Shahla Rezaei, Fatemeh Jafari, Kamran Hessami, Mehdi Abedi, Mohammad Jalali, Pedram Keshavarzi, Saeed Shahabi, Ali Asghar Kolahi, Kristin Carson-Chahhoud, Amirhossein Sahebkar & Saeid Safiri. (2020) The effect of voglibose on metabolic profiles in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of clinical trials. Pharmacological Research 159, pages 104988.
Crossref
Crossref
Masahiro Takahashi, Misa Shibasaki, Hirotoshi Echizen & Akifumi Kushiyama. (2020) Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: A meta-analysis. PLOS ONE 15:7, pages e0236603.
Crossref
Crossref
Takeshi Horii, Makiko Iwasawa, Jyunichi Shimizu & Koichiro Atsuda. (2019) Comparing treatment intensification and clinical outcomes of metformin and dipeptidyl peptidase‐4 inhibitors in treatment‐naïve patients with type 2 diabetes in Japan. Journal of Diabetes Investigation 11:1, pages 96-100.
Crossref
Crossref
Sanaz Kamalinia, Robert G. Josse, Patrick J. Donio, Lindsay Leduc, Baiju R. Shah & Sheldon W. Tobe. (2019) Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta‐analysis. Endocrinology, Diabetes & Metabolism 3:1.
Crossref
Crossref
Kohei Kaku, Koichi Kisanuki, Mari Shibata & Takashi Oohira. (2019) Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus. Drug Safety 42:11, pages 1311-1327.
Crossref
Crossref
Eiichi Araki, Yuriko Unno, Yuko Tanaka, Wataru Sakamoto & Yuki Miyamoto. (2019) Long-Term Efficacy and Safety of Linagliptin in a Japanese Population with Type 2 Diabetes Aged ≥ 60 Years Treated with Basal Insulin: A Randomised Trial. Advances in Therapy 36:10, pages 2697-2711.
Crossref
Crossref
Zhaoliang Li, Liang Zhao, Leilei Yu & Jie Yang. (2019) Head-to-Head Comparison of the Hypoglycemic Efficacy and Safety Between Dipeptidyl Peptidase-4 Inhibitors and α-Glucosidase Inhibitors in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials. Frontiers in Pharmacology 10.
Crossref
Crossref
Yumie Takeshita, Yuki Kita, Ken‐ichiro Kato, Takehiro Kanamori, Hirofumi Misu, Shuichi Kaneko & Toshinari Takamura. (2018) Effects of metformin and alogliptin on body composition in people with type 2 diabetes. Journal of Diabetes Investigation 10:3, pages 723-730.
Crossref
Crossref
Juan Ling, Peng Cheng, Long Ge, Ding-hua Zhang, An-chen Shi, Jin-hui Tian, Ya-jing Chen, Xiu-xia Li, Jing-yun Zhang & Ke-hu Yang. (2018) The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials. Acta Diabetologica 56:3, pages 249-272.
Crossref
Crossref
N. A. PetuninaA. L. Terekhova. (2019) Reliable choice in therapy of type 2 diabetes mellitus: focus on alogliptin. Medical Council:21, pages 138-145.
Crossref
Crossref
Xueying Gao, Xiaoling Cai, Wenjia Yang, Yifei Chen, Xueyao Han & Linong Ji. (2017) Meta‐analysis and critical review on the efficacy and safety of alpha‐glucosidase inhibitors in Asian and non‐Asian populations. Journal of Diabetes Investigation 9:2, pages 321-331.
Crossref
Crossref
Lisanne C. de Vos, Thushan S. Hettige & Mark E. Cooper. (2018) New Glucose-Lowering Agents for Diabetic Kidney Disease. Advances in Chronic Kidney Disease 25:2, pages 149-157.
Crossref
Crossref
Sofie Hædersdal, Asger Lund, Filip K. Knop & Tina Vilsbøll. (2018) The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes. Mayo Clinic Proceedings 93:2, pages 217-239.
Crossref
Crossref
Yuli Cai, Tianshu Zeng, Zhongyuan Wen & Lulu Chen. (2017) Ethnic Differences in Efficacy and Safety of Alogliptin: A Systematic Review and Meta-Analysis. Diabetes Therapy 9:1, pages 177-191.
Crossref
Crossref
Jagriti Upadhyay, Stergios A. Polyzos, Nikolaos Perakakis, Bindiya Thakkar, Stavroula A. Paschou, Niki Katsiki, Patricia Underwood, Kyung-Hee Park, Jochen Seufert, Eun Seok Kang, Elliot Sternthal, Asterios Karagiannis & Christos S. Mantzoros. (2018) Pharmacotherapy of type 2 diabetes: An update. Metabolism 78, pages 13-42.
Crossref
Crossref
Changyu Pan, Ping Han, Qiuhe Ji, Chengjiang Li, Juming Lu, Jinkui Yang, Wenhui Li, Jiaoe Zeng, An‐Tsz Hsieh & Juliana Chan. (2016) Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double‐blind placebo‐controlled Phase 3 study in mainland China, Taiwan, and Hong Kong. Journal of Diabetes 9:4, pages 386-395.
Crossref
Crossref
Islam Y. Elgendy, Ahmed N. Mahmoud, Amr F. Barakat, Akram Y. Elgendy, Marwan Saad, Ahmed Abuzaid, Siddarth A. Wayangankar & Anthony A. Bavry. (2016) Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials. American Journal of Cardiovascular Drugs 17:2, pages 143-155.
Crossref
Crossref
Xiafei Lyu, Xiaolin Zhu, Bin Zhao, Liang Du, Dawei Chen, Chun Wang, Guanjian Liu & Xingwu Ran. (2017) Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials. Scientific Reports 7:1.
Crossref
Crossref
Kohei Kaku, Shuuji Sumino, Masafumi Katou, Yuya Nishiyama & Yoshinobu Kinugawa. (2017) Randomized, double-blind, phase III study to evaluate the efficacy and safety of once-daily treatment with alogliptin and metformin hydrochloride in Japanese patients with type 2 diabetes. Diabetes, Obesity and Metabolism 19:3, pages 463-467.
Crossref
Crossref
Kayo Fujita, Masayuki Kaneko & Mamoru Narukawa. (2016) Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions. Clinical Drug Investigation 37:3, pages 219-232.
Crossref
Crossref
Kenichi Tanaka, Yosuke Okada, Hiroko Mori, Megumi Miyazaki, Fumi Kuno, Satomi Sonoda, Kei Sugai, Maiko Hajime, Akira Kurozumi, Manabu Narisawa, Keiichi Torimoto, Tadashi Arao, Shinichiro Mine & Yoshiya Tanaka. (2017) Comparative analysis of the effects of alogliptin and vildagliptin on glucose metabolism in type 2 diabetes mellitus. Endocrine Journal 64:2, pages 179-189.
Crossref
Crossref
Xiaolong Chen, Yuele Lu, Yongxian Fan & Yinchu Shen. 2017. Validamycin and its Derivatives. Validamycin and its Derivatives
237
278
.
Satoshi Ida, Kazuya Murata, Katunori Betou, Chiaki Kobayashi, Yuki Ishihara, Kanako Imataka, Akihiro Uchida, Kou Monguchi, Ryutaro Kaneko, Ryoko Fujiwara & Hiroka Takahashi. (2016) Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study. Cardiovascular Diabetology 15:1.
Crossref
Crossref
Hui WangXiufei LiuMin LongYi HuangLinlin ZhangRui ZhangYi ZhengXiaoyu LiaoYuren WangQian LiaoWenjie LiZili TangQiang TongXiaocui WangFang FangMontserrat Rojo de la VegaQin OuyangDonna D. ZhangShicang YuHongting Zheng. (2016) NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. Science Translational Medicine 8:334.
Crossref
Crossref
Xiao-Wu Chen, Zhi-Xu He, Zhi-Wei Zhou, Tianxin Yang, Xueji Zhang, Yin-Xue Yang, Wei Duan & Shu-Feng Zhou. (2015) An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology 42:12, pages 1225-1238.
Crossref
Crossref
Xiaoling Cai, Wenjia Yang, Lingli Zhou, Simin Zhang, Xueyao Han & Linong Ji. (2015) Comparisons of the efficacy of glucose control, lipid profile, and β-cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis. Endocrine 50:3, pages 590-597.
Crossref
Crossref
Xiao-Wu Chen, Zhi-Xu He, Zhi-Wei Zhou, Tianxin Yang, Xueji Zhang, Yin-Xue Yang, Wei Duan & Shu-Feng Zhou. (2015) Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology 42:10, pages 999-1024.
Crossref
Crossref
Xiaoling Cai, Xueyao Han, Yingying Luo & Linong Ji. (2014)
Efficacy of dipeptidyl‐peptidase‐4 inhibitors and impact on
β
‐cell function in
A
sian and
C
aucasian type 2 diabetes mellitus patients: A meta‐analysis在亚洲人和白种人的2型糖尿病患者中DPP‐4抑制剂的疗效及对
β
细胞功能的影响：一项meta分析
. Journal of Diabetes 7:3, pages 347-359.
Crossref
Crossref
Gillian M. Keating. (2015) Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs 75:7, pages 777-796.
Crossref
Crossref
Nobuya Inagaki, Hitoshi Onouchi, Hideaki Maezawa, Shingo Kuroda & Kohei Kaku. (2015) Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study. The Lancet Diabetes & Endocrinology 3:3, pages 191-197.
Crossref
Crossref
Hiromi HamamotoKoji NakanishiMitsuhiko Noda. (2015) Analyzing the Factors Contributing to Withdrawal from Insulin Therapy following Additional Administration of Alogliptin: Retrospective Study after Removing Glucotoxicity with Insulin. Japanese Clinical Medicine 6, pages JCM.S27202.
Crossref
Crossref
George Grunberger. (2014) Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials. European Journal of Clinical Pharmacology 70:11, pages 1277-1289.
Crossref
Crossref
Paul Craddy, Hannah-Jayne Palin & K. Ian Johnson. (2014) Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison. Diabetes Therapy 5:1, pages 1-41.
Crossref
Crossref
Tsuyoshi Tanaka, Hiroyuki Goto, Rika Araki, Mika Yamamoto, Takashi Tanaka, Ryoko Fujiwara & Kazuya Murata. (2014) Efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes switched from glinides. Journal of Diabetes Investigation 5:2, pages 199-205.
Crossref
Crossref
Kohzo Takebayashi, Shintaro Sakurai, Tatsuhiko Suzuki, Kenichiro Hori, Tomoko Terasawa, Rika Naruse, Kenji Hara, Mariko Suetsugu, Takafumi Tsuchiya, Hiromi Aoki, Takashi Hamasaki, Hiroshi Shuutou & Toshihiko Inukai. (2014) Effect of combination therapy with alogliptin and lansoprazole on glycemic control in patients with type 2 diabetes. Endocrine Journal 61:10, pages 1031-1039.
Crossref
Crossref
Asres Berhan & Yifru Berhan. (2013) Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies. BMC Endocrine Disorders 13:1.
Crossref
Crossref
Jaime A. Davidson. (2013) The Placement of DPP-4 Inhibitors in Clinical Practice Recommendations for the Treatment of Types 2 Diabetes. Endocrine Practice 19:6, pages 1050-1061.
Crossref
Crossref
N. Inagaki, H. Watada, M. Murai, T. Kagimura, Y. Gong, S. Patel & H.-J. Woerle. (2013) Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes. Diabetes, Obesity and Metabolism 15:9, pages 833-843.
Crossref
Crossref
Y. G. Kim, S. Hahn, T. J. Oh, S. H. Kwak, K. S. Park & Y. M. Cho. (2013) Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 56:4, pages 696-708.
Crossref
Crossref
Makoto Ayaori, Naotsugu Iwakami, Harumi Uto‐Kondo, Hiroki Sato, Makoto Sasaki, Tomohiro Komatsu, Maki Iizuka, Shunichi Takiguchi, Emi Yakushiji, Kazuhiro Nakaya, Makiko Yogo, Masatsune Ogura, Bonpei Takase, Takehiko Murakami & Katsunori Ikewaki. (2013) Dipeptidyl Peptidase‐4 Inhibitors Attenuate Endothelial Function as Evaluated by Flow‐Mediated Vasodilatation in Type 2 Diabetic Patients. Journal of the American Heart Association 2:1.
Crossref
Crossref
Yoshiki Kusunoki, Tomoyuki Katsuno, Makiko Myojin, Kana Miyakoshi, Takashi Ikawa, Toshihiro Matsuo, Fumihiro Ochi, Masaru Tokuda, Kazuki Murai, Masayuki Miuchi, Tomoya Hamaguchi, Jun-ichiro Miyagawa & Mitsuyoshi Namba. (2013) Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin. Endocrine Journal 60:4, pages 431-439.
Crossref
Crossref
Yutaka Seino, Shinzo Hiroi, Masashi Hirayama & Kohei Kaku. (2012) Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial with an open‐label, long‐term extension study. Journal of Diabetes Investigation 3:6, pages 517-525.
Crossref
Crossref
Y. Seino, Y. Miyata, S. Hiroi, M. Hirayama & K. Kaku. (2012) Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial with an open‐label, long‐term extension study. Diabetes, Obesity and Metabolism 14:10, pages 927-936.
Crossref
Crossref
Tomomi Kimura, Kazuhito Shiosakai, Yasuaki Takeda, Shinji Takahashi, Masahiko Kobayashi & Motonobu Sakaguchi. (2012) Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan. Pharmaceutics 4:3, pages 479-493.
Crossref
Crossref
R. Kawamori, N. Inagaki, E. Araki, H. Watada, N. Hayashi, Y. Horie, A. Sarashina, Y. Gong, M. von Eynatten, H. J. Woerle & K. A. Dugi. (2012) Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator‐controlled, double‐blind study. Diabetes, Obesity and Metabolism 14:4, pages 348-357.
Crossref
Crossref